Business Wire

WISDOM

14.10.2021 18:02:04 CEST | Business Wire | Press release

Share
Clubhouse Meets Masterclass! Wisdom App Launches World’s Largest Mentorship Platform via Social Audio

Wisdom – the social audio app built to democratise mentorship – is now live in the UK, the US, Australia, and Canada. Founded by Dayo Akinrinade, the Wisdom app is an inclusive space where diverse people come together to have conversations that matter.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005070/en/

On a mission to become the next big social audio community, Wisdom taps into the intimacy and authenticity provided by the emerging medium. Drop-in social audio is transforming social networking because it takes interactions and conversations back to their roots. As the oldest medium, and one that is the most “human” of all societal interactions, audio is the antithesis of the heavily filtered nature of today’s visual-led apps and one which helps amplify voices of all groups and communities.

Wisdom is the latest app to launch in the white hot social audio market. Unlike other social audio applications, like Clubhouse, Wisdom is designed from the ground up to promote conversations that matter: conversations of substance on a topic of importance. Members can chat live with experts in dozens of topics from parenting, fitness, and dating to startups, mental health, and beauty. They can listen live or playback the recordings in their own time.

In Wisdom, when a mentor starts a talk, listeners can queue up to ask questions. A timer keeps the conversation moving so no one guest can monopolise the conversation; making sure all voices are heard. Inspired by Tiktok, Wisdom leverages an algorithm-first design that quickly learns what members like to listen to. Talk recommendations are made by a deep-learning neural network.

Dayo Akinrinade, founder and CEO of Wisdom, said : “I founded Wisdom to democratise access to mentorship. During my time at OneTech , London's largest diversity in startups programme, I noticed that diverse individuals from underrepresented groups lack access to mentoring. I also personally experienced how impossible it is to use platforms like LinkedIn for mentoring. The inboxes of experts are inundated with “pick your brain” requests which end up ignored unless the request is via a warm introduction, which is itself a crystallisation of systemic inequality.”

A global platform for mentorship

Connecting with others in a meaningful way has been proven to make people happier, with deep conversations with strangers more enjoyable than small talk. Wisdom will cultivate this, with thousands of people already signed up as mentors, making it the largest platform for mentorship in the world. These experts will be able to use Wisdom to share their knowledge, interact directly with their audience and give back while getting on the ground floor of the next big social audio community.

Though the platform will be free to members, as part of its mission to democratise mentorship, Wisdom will also empower its mentors through monetisation tools so they can grow their own businesses. Monetisation features will be added to Wisdom later this year.

Akinrinade added: “Consider that Masterclass has no more than hundreds of experts on its platform and does not allow deep interactions and is not free. With Wisdom, we are building something very different. Ultimately what we are building with Wisdom is a new social graph … the Mentor Graph. This is not a messy ‘talk graph’ of anyone on any topic but a social graph of the people who can help jumpstart a career, or change a life for the better. People today hunger for conversations that matter. We believe Wisdom is the platform where these conversations can live.”

The Wisdom app is available for download today for iPhone. Android is coming soon.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye